BioCentury
ARTICLE | Clinical News

Shire releases Phase III Reminyl data

April 7, 2000 7:00 AM UTC

Shire (LSE:SHP, SHPGY) and partner Janssen Pharmaceutica (Beerse, Belgium) said that patients treated with 16 mg/day and 24 mg/day of SHP's Reminyl galantamine had significantly better scores on cogni...